297 related articles for article (PubMed ID: 27178014)
1. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature.
Singh D; Narayanan S; Vicknasingam B
Brain Res Bull; 2016 Sep; 126(Pt 1):41-46. PubMed ID: 27178014
[TBL] [Abstract][Full Text] [Related]
2. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
[TBL] [Abstract][Full Text] [Related]
3. Do You Get What You Paid For? An Examination of Products Advertised as Kratom.
Griffin OH; Daniels JA; Gardner EA
J Psychoactive Drugs; 2016; 48(5):330-335. PubMed ID: 27669103
[TBL] [Abstract][Full Text] [Related]
4. Update on the Pharmacology and Legal Status of Kratom.
Prozialeck WC
J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
[TBL] [Abstract][Full Text] [Related]
5. Mitragynine concentrations in two fatalities.
Domingo O; Roider G; Stöver A; Graw M; Musshoff F; Sachs H; Bicker W
Forensic Sci Int; 2017 Feb; 271():e1-e7. PubMed ID: 28089300
[TBL] [Abstract][Full Text] [Related]
6. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
Hassan Z; Muzaimi M; Navaratnam V; Yusoff NH; Suhaimi FW; Vadivelu R; Vicknasingam BK; Amato D; von Hörsten S; Ismail NI; Jayabalan N; Hazim AI; Mansor SM; Müller CP
Neurosci Biobehav Rev; 2013 Feb; 37(2):138-51. PubMed ID: 23206666
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.
Warner ML; Kaufman NC; Grundmann O
Int J Legal Med; 2016 Jan; 130(1):127-38. PubMed ID: 26511390
[TBL] [Abstract][Full Text] [Related]
9. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
10. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia.
Singh D; Müller CP; Vicknasingam BK; Mansor SM
J Psychoactive Drugs; 2015; 47(2):125-31. PubMed ID: 25950592
[TBL] [Abstract][Full Text] [Related]
11. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
[TBL] [Abstract][Full Text] [Related]
12. Kratom use and mental health: A systematic review.
Swogger MT; Walsh Z
Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of deaths associated with kratom use.
Corkery JM; Streete P; Claridge H; Goodair C; Papanti D; Orsolini L; Schifano F; Sikka K; Körber S; Hendricks A
J Psychopharmacol; 2019 Sep; 33(9):1102-1123. PubMed ID: 31429622
[TBL] [Abstract][Full Text] [Related]
14. Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.
Cinosi E; Martinotti G; Simonato P; Singh D; Demetrovics Z; Roman-Urrestarazu A; Bersani FS; Vicknasingam B; Piazzon G; Li JH; Yu WJ; Kapitány-Fövény M; Farkas J; Di Giannantonio M; Corazza O
Biomed Res Int; 2015; 2015():968786. PubMed ID: 26640804
[TBL] [Abstract][Full Text] [Related]
15. Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations.
Helander A; Rylski A
Drug Test Anal; 2023 Feb; 15(2):213-219. PubMed ID: 36258649
[TBL] [Abstract][Full Text] [Related]
16. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.
Fowble KL; Musah RA
Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866
[TBL] [Abstract][Full Text] [Related]
17. Fatality of 33-Year-Old Man Involving Kratom Toxicity.
Matson M; Schenk N
J Forensic Sci; 2019 Nov; 64(6):1933-1935. PubMed ID: 31121058
[TBL] [Abstract][Full Text] [Related]
18. Neurobiology of Kratom and its main alkaloid mitragynine.
Suhaimi FW; Yusoff NH; Hassan R; Mansor SM; Navaratnam V; Müller CP; Hassan Z
Brain Res Bull; 2016 Sep; 126(Pt 1):29-40. PubMed ID: 27018165
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa).
Kapp FG; Maurer HH; Auwärter V; Winkelmann M; Hermanns-Clausen M
J Med Toxicol; 2011 Sep; 7(3):227-31. PubMed ID: 21528385
[TBL] [Abstract][Full Text] [Related]
20. Is kratom (
Leong Abdullah MFI; Tan KL; Narayanan S; Yuvashnee N; Chear NJY; Singh D; Grundmann O; Henningfield JE
Clin Toxicol (Phila); 2021 May; 59(5):400-408. PubMed ID: 32870119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
